• news.cision.com/
  • H. Lundbeck A/S/
  • Merck & Co., Inc. and Lundbeck discontinue joint development program for gaboxadol, an investigational compound for insomnia
English

Merck & Co., Inc. and Lundbeck discontinue joint development program for gaboxadol, an investigational compound for insomnia

Report this content 

                        
Merck & Co., Inc. and H. Lundbeck A/S announced today the discontinuation of
the joint development program for gaboxadol, an investigational new medicine
for the treatment of insomnia currently in phase III development. Data from
recently completed clinical studies suggest that the overall clinical profile
for gaboxadol in insomnia does not support further development. 





                                            

                

            

        

    

    



    

        
 Subscribe

        

            

        

    


        

            
        

        

            
        

        



    

        
 Documents & Links